CG Health Department Issues Blacklisting Notice to Pharmaceutical Company Over Drug Quality Concerns

The Chhattisgarh health department, committed to zero tolerance for quality control, has issued a show-cause notice to M/s. Effi Parenterals, indicating a potential blacklisting. This action follows the discovery of significant quality issues with the company’s Albendazole tablets. The department ensures that all drug batches supplied to health institutions undergo rigorous quality testing by NABL-accredited labs before distribution. This process is in place to guarantee that only approved medications reach patients. Specifically, the Albendazole tablets IP 400 mg (Drug Code – D12) supplied by Effi Parenterals, specifically batches PGT25451, PGT25450, PGT25480, and PGT25229, were tested at the State Drug Testing and Research Laboratory, Raipur, before being sent to hospitals. These batches failed the quality tests. Consequently, the health department has issued a show-cause notice for blacklisting the firm and instructed the company to retrieve all failed batches from drug warehouses.